Zeus Names New Chief Executive Officer
Get Alerts BDX Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
EPS Growth %: +2.8%
Join SI Premium – FREE
- Zeus, a leading supplier of custom polymer components to the world's most innovative medical device and industrial companies, names Padraic "Paddy" O'Brien as new CEO
- O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership
- O'Brien currently serves as Worldwide President of BD Peripheral Intervention
O'Brien is currently Worldwide President of BD Peripheral Intervention at Becton, Dickinson, and Company (NYSE: BDX), a medical technology company focused on advancing clinical therapy for patients and clinical process for healthcare providers.
Before that, he held various leadership positions within BD, where he developed an extensive and consistent track record of delivering durable, sustainable growth while creating a winning culture. From 2001-2016, he held a series of ascending management positions within Bard until BD acquired the company in
O'Brien holds a Bachelor of Science in Combined Sciences (Biology and Chemistry) from Santa Clara University.
"We are thrilled to welcome Paddy as the new CEO of Zeus," said
About Zeus
Zeus, headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/zeus-names-new-chief-executive-officer-302089568.html
SOURCE Zeus Company, LLC
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JinkoSolar Unveils Tiger Neo 5.0 All-Black Residential Solar Module with 25.52% Efficiency
- OMODA & JAECOO Opens Professional Training Centre and Establishes Dealer Association, Accelerating Localisation Efforts in Europe
- OMODA & JAECOO to Showcase Purpose-Built L4 Robotaxi, Bringing a New Driverless Mobility Experience to Global Markets
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share